2',3'-Dideoxyinosine inhibits the humoral immune response in female B6C3F1 mice by targeting the B lymphocyte

Toxicology and Applied Pharmacology

Volumn 145, Issue 2, 1997, Pages 260-267

  Phillips, Kathleen E ^a   Munson, Albert E ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; PURINE NUCLEOSIDE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOTOXICITY; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0031213557     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.1997.8150     Document Type: Article

References (22)

1. Bartlett M. S. Sub-sampling for attributes. J. R. Stat. Soc. Suppl. 4:1937;131-135.
2. Cao W., Sikorski E. E., Fuchs B. A., Stern M. L., Luster M. I., Munson A. E. The B lymphocyte is the immune cell target for 2′,3′-dideoxyadenosine. Toxicol. Appl. Pharmacol. 105:1990;492-502.
3. Chen C., Vazquez-Padua M., Cheng Y. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. Mol. Pharmacol. 39:1991;625-628.
4. Cooley T. P., Kunches L. M., Saunders C. A., Ritter J. K., Perkins C. J., McLaren C., McCafferey R. P., Liebman H. A. Once-daily administration of 2′,3′-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. N. Engl. J. Med. 322:1990;1340-1345.
5. Du D. L., Volpe D. A., Murphy M. J. Jr., Grieshaber C. K. Comparative myelotoxic effects of two anti-HIV agents on human and murine hematopoietic progenitor cells [abstract 2411]. Proc. Am. Assoc. Canc. Res. 30:1989;606.
6. Dunnett C. W. A multiple comparison procedure for comparing several treatments with a control. J. Am. Stat. Assoc. 50:1955;1096-1121.
7. Jerne N. K., Nordin A. A., Henry C. The agar plaque technique for recognizing antibody producing cells. Cell-Bound Antibody. 1963;Wistar Institute Press, Philadelphia. p. 109-120.
8. Luster M. I., Rosenthal G. J., Cao W., Thompson M. B., Munson A. E., Prejean J. D., Shopp G., Fuchs B. A., Germolec D. R., Tomaszewski J. E. Experimental studies of the hematologic and immune system toxicity of nucleoside derivatives used against HIV infection. Int. J. Immunopharmacol. 13:1991;99-107.
9. McGowan J. J., Tomaszewski J. E., Cradock J., Hoth D., Grieshaber C. K., Broder S., Mitsuya H. Overview of the preclinical development of an antiretroviral drug, 2′,3′-dideoxyinosine. Rev. Inf. Dis. 12:1990;S513-S521.
10. Medina D. J., Tsai C., Hsiung G. D., Cheng Y. Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-human immunodeficiency virus dideoxynucleosides. Antimicrob. Agents Chem. 38:1994;1824-1828.
11. Mishell B. B., Shiigi S. M. Selected Methods in Cellular Immunology. 1980;Freeman, San Francisco.
12. Mishell R. I., Dutton R. W. Immunization of dissociated mouse spleen cell culture from normal mice. J. Exp. Med. 126:1967;423-442.
13. Mitsuya H., Jarrett R. F., Matsukura M., Veronese F. D., DeVico A. L., Sarngadharan M. G., Johns D. G., Reitz M. S., Broder S. Long-term inhibition of human T-lymphotropic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2′,3′-dideoxynucleosidesin vitro. Proc. Natl. Acad. Sci. USA. 84:1987;2033-2037.
14. Mossman T. R. Cytokines, differentiation and functions of subsets of CD4 and CD8 T cells. Behring Inst. Mitt. 96:1995;1-6.
15. K. E. Phillips, J. A. McCay, R. D. Brown, D. L. Musgrove, B. J. Meade, L. F. Butterworth, S. Wilson, M. I. Luster, K. L. White, Jr. A. E. Munson, 1996, Immunotoxicity of 2′,3′-dideoxyinosine in female B6C3F1 mice.
16. Temple L., Kawabata T. T., Munson A. E., White K. L. Jr. Comparison of ELISA and plaque-forming cell assay for measuring the humoral immune response to sRBC in animals treated with benzo[a. Fundam. Appl. Toxicol. 21:1993;412-419.
17. Tukey J. W. Exploratory Data Analysis. 1977;Addison-Wesley, Reading.
18. Voisin E. M., Ruthsatz M., Collins J. M., Hoyle P. C. Extrapolation of animal toxicity to humans: Interspecies comparisons in drug development. Reg. Toxicol. Pharmacol. 12:1990;107-116.
19. Waqar M. A., Evans M. J., Manly K. F., Hughes R. G., Huberman J. A. Effects of 2′,3′-dideoxynucleosides on mammalian cells and viruses. J. Cell. Physiol. 121:1984;402-408.
20. Yarchoan R., Mitsuya H., Thomas R. V., Pluda J. M., Hartman N. R., Perno C. F., Marczyk K. S., Allain J. P., Johns D. G., Broder S. In vivo activity against HIV and favorable toxicity profile of 2′,3′-dideoxyinosine. Science. 245:1989;412-415.
21. Yarchoan R., Thomas R., Allen J. P., McAtee N., Dubinsky R., Mitsuya H., Lawley T., Safai B., Myers C., Perno C., Klecker R., Wills R., Fischl M., McNeely M., Pluda J., Leuther M., Collins J., Broder S. Phase I studies of 2′,3′-dideoxycytidine in sever human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet. 1:1988;76-81.
22. Youssef J. A., Mostafa M. Z. Disruption of mitochondrial energetics and DNA synthesis by the anti-AIDS drug dideoxyinosine. Toxicol. Lett. 60:1992;197-202.